Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Author(s): Laila Salah Shamseldin, Mohamed Mohamed Shawqi, Noor Adel Al Hashem, Majd Aleslam Hussein Alhyari, Hossam Aldein Samir Abd Elazeem, Shrouk M. Elghazaly, Aboalmagd Hamdallah*, Khaled Mohamed Ragab and Anas Zakarya Nourelden

Volume 17, Issue 2, 2021

Published on: 13 November, 2020

Page: [184 - 192] Pages: 9

DOI: 10.2174/1573397116666201113085444

Price: $65

Abstract

Background: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by progressive swelling and stiffness in the joints. Mavrilimumab is a human monoclonal antibody that may block the autoimmune mechanism of the antibodies causing RA.

Objective: We aim to assess the safety and efficacy of Mavrilimumab in treating rheumatoid arthritis.

Methods: We conducted an online search using PubMed, Scopus, Web of Science, and Cochrane CENTRAL till June 2019, and updated the search in May 2020, using relevant keywords. We screened studies for eligibility. Data were extracted from eligible studies and pooled as Risk ratio (RR) with a 95% confidence interval (CI), using Review Manager software (ver.3.5).

Results: Five studies (with 1145 patients) were eligible to our criteria. Pooled result from three trials showed a significant reduction in Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) remission < 2.6 after 12 weeks (RR = 3.31, 95% CI [1.53, 7.18], P = 0.002), American College of Rheumatology (ACR) 20, after 12 weeks (RR = 2.38, 95% CI [1.80, 3.16], P < 0.00001), ACR 50, after 12 weeks (RR = 2.93, 95% CI [1.67, 5.15], P = 0.0002), ACR 70, after 12 weeks (RR = 4.90, 95% CI [1.60, 15.00], P = 0.005). Mavrilimumab not associated with a significant adverse event (RR = 1.22, 95% CI [0.89, 1.68], P = 0.22).

Conclusion: We found that subcutaneous Mavrilimumab was effective and well-tolerating in treating RA patients, with no significant adverse events.

Keywords: Mavrilimumab, CAM-3001, monoclonal antibody, rheumatoid Arthritis, antirheumatic Agents, meta-analysis.

« Previous Next »
Graphical Abstract

[1]
Carbone F, Bonaventura A, Liberale L, Paolino S, Torre F, Dallegri F. Atherosclerosis in rheumatoid arthritis: Promoters and opponents. Clin Rev Allergy Immunol Springer 2020; 58(1): 1-14.
[2]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388(10055): 2023-38.
[http://dx.doi.org/10.1016/S0140-6736(16)30173-8] [PMID: 27156434]
[3]
Tuncer T, Gilgil E, Kaçar C, et al. Prevalence of rheumatoid arthritis and spondyloarthritis in Turkey: A nationwide study. Arch Rheumatol 2017; 33(2): 128-36.
[http://dx.doi.org/10.5606/ArchRheumatol.2018.6480] [PMID: 30207568]
[4]
Bao YK, Weide LG, Ganesan VC, et al. High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. J Diabetes 2019; 11(4): 273-9.
[http://dx.doi.org/10.1111/1753-0407.12856] [PMID: 30226016]
[5]
Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int 2017; 37(9): 1551-7.
[http://dx.doi.org/10.1007/s00296-017-3726-1] [PMID: 28455559]
[6]
Lanzillo CF, Hayden SR. Rheumatoid Arthritis.Rosen and Barkin’s 5-Minute Emergency Medicine Consult: Fifth Edition Wolters Kluwer Health Adis (ESP). 2014.
[7]
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76(6): 960-77.
[http://dx.doi.org/10.1136/annrheumdis-2016-210715] [PMID: 28264816]
[8]
Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50(5): 1400-11.
[http://dx.doi.org/10.1002/art.20217] [PMID: 15146409]
[9]
Bell AL, Magill MK, McKane WR, Kirk F, Irvine AE. Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 1995; 14(5): 177-82.
[http://dx.doi.org/10.1007/BF00262295] [PMID: 7536953]
[10]
Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8(7): 533-44.
[http://dx.doi.org/10.1038/nri2356] [PMID: 18551128]
[11]
Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013; 34(2): 81-9.
[http://dx.doi.org/10.1016/j.it.2012.08.006] [PMID: 23000011]
[12]
Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10(6): 425-34.
[http://dx.doi.org/10.1038/nrc2843] [PMID: 20495576]
[13]
Croxford AL, Lanzinger M, Hartmann FJ, et al. The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. Immunity 2015; 43(3): 502-14.
[http://dx.doi.org/10.1016/j.immuni.2015.08.010] [PMID: 26341401]
[14]
Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IPG-CSF. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5(10): 554-9.
[http://dx.doi.org/10.1038/nrrheum.2009.178] [PMID: 19798030]
[15]
Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis 2018; 10(2): 29-38.
[http://dx.doi.org/10.1177/1759720X17752036] [PMID: 29387176]
[16]
Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(4)(Suppl. 98): 39-44.
[PMID: 27586802]
[17]
Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91(12): 5592-6.
[http://dx.doi.org/10.1073/pnas.91.12.5592] [PMID: 8202532]
[18]
Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Chin Integr Med 2009; 7(9): 889-96.
[http://dx.doi.org/10.3736/jcim20090918]
[19]
Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011. Available from: http://handbook.cochrane.org
[20]
Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70(5): 679-89.
[http://dx.doi.org/10.1002/art.40420] [PMID: 29361199]
[21]
Study Quality Assessment Tools. National Heart, Lung, and Blood Institute (NHLBI). Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
[22]
Burmester GR, Weinblatt ME, McInnes IB, et al. EARTH Study Group. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72(9): 1445-52.
[http://dx.doi.org/10.1136/annrheumdis-2012-202450] [PMID: 23234647]
[23]
Burmester GR, McInnes IB, Kremer J, et al. EARTH EXPLORER 1 study investigators. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017; 76(6): 1020-30.
[http://dx.doi.org/10.1136/annrheumdis-2016-210624] [PMID: 28213566]
[24]
Takeuchi T, Tanaka Y, Close D, Godwood A, Wu CY, Saurigny D. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod Rheumatol 2015; 25(1): 21-30.
[http://dx.doi.org/10.3109/14397595.2014.896448] [PMID: 24720551]
[25]
Michael E. Weinblatt, MD, 1 Iain B. McInnes, MD, 2 Joel M. Kremer, MD, 3 Pedro Miranda, MD, 4 Jiri Vencovsky, MD, 5 Xiang Guo, PhD, 6 Wendy I. White, PhD, 6 Patricia C. Ryan, PhD, 6 Alex Godwood, PhD, 7 Marius Albulescu, MD, 7 David Close, PhD, 7,^ and Ge M. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Int J Lab Hematol 2017; 38(1): 42-9.
[PMID: 27577964]
[26]
Mortensen JH, Guo X, De Los Reyes M, et al. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients. Clin Exp Rheumatol 2019; 37(1): 73-80.
[PMID: 30418117]
[27]
Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011; 70(9): 1542-9.
[http://dx.doi.org/10.1136/ard.2010.146225] [PMID: 21613310]
[28]
Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109(4): 933-8.
[http://dx.doi.org/10.1378/chest.109.4.933]

Rights & Permissions Print Cite
Article Metrics
69
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy